Hepatocellular carcinoma (HCC) is the most common liver malignancy, accounting for 90% of liver tumors. The posing method in the paper is critical evidence to DrAid™ CT Liver Cancer D&T in enriching HCC and non-HCC representation and classification, marking research capabilities and international scientific influence of VinBrain.

🔗  Read it in full version: https://lnkd.in/gNGA_WHT

VinBrain's scientific research-focused investment increases the reliability and accuracy of go-to-market medical solutions by international standards, which sets VinBrain apart from other technology product development units.

Our FDA and CE Marking for DrAid™ CT Liver Cancer D&T is in progress and ready to assist oncologists overseas in SEA, USA and Europe in 2024.